ORCHPHARMA Orchid Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Orchid Pharma reported a challenging Q3 FY26 with sales declining 5% YoY to INR 207 crores and EBITDA margin compressing to 6% due to continued pricing pressure in the global antibiotics market and lower contribution from regulated markets. Despite these headwinds, the company saw sequential volume improvement, launched Exblifep in new geographies (Spain, Italy, UAE, Kuwait), and progressed its 7ACA project towards mechanical completion by September 2026. R&D investments increased to 1.5% of sales, and cost structures were reviewed to mitigate impacts.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 4.6%, net profit down 160.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 263 | 194 −13% | 207 −5% |
| EBITDA | 30 | 26 | 28 | -6 | -1 −105% | 2 −94% |
| Net profit | 27 | 21 | 22 | -6 | -6 −121% | -13 −161% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
